Takeda’s Millennium Seeks Modest Acquisitions, But Could Go Bigger
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical has freed its U.S.-based Millennium biotech unit to seek its own mergers and acquisitions among the more modest players in the drug making industry. CEO Deborah Dunshire said in an interview that Millennium is not likely to try to acquire a large company, noting Takeda's own avoidance of such deals. She said a Millennium M&A is likely to center on "smaller, single-product acquisitions." She did not, however, rule out a larger transaction as big as the $10 billion range. (Click here for more - a subscription may be required
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.